Managing asthma has never involved more options than it does in 2026. From daily inhalers to precision biologics and cutting-edge clinical trials, the landscape of asthma care is evolving rapidly — and patients across the United States have more reason than ever to stay informed.
The Foundation of Asthma Treatment: Inhalers and Controllers
For most people living with asthma, inhaled medications remain the cornerstone of day-to-day management. These treatments deliver medication directly to the airways, helping to reduce inflammation and prevent or relieve symptoms. Controller inhalers are used regularly to maintain stable lung function, while rescue inhalers address sudden flare-ups when they occur.
Despite the availability of these therapies, a significant number of patients find that standard inhaled treatments do not fully control their condition. When asthma remains moderate to severe even with consistent inhaler use, physicians often look to additional options — including a newer class of treatments known as biologics — to better manage the disease.
Biologics: Targeting Asthma at Its Biological Roots
Biologic medicines represent a major advancement in asthma care. Rather than broadly suppressing symptoms, each biologic targets a specific immune pathway involved in triggering asthma attacks. Doctors use measurable biological markers — such as IgE antibodies, eosinophil levels, and fractional exhaled nitric oxide — to identify the type of asthma driving a patient’s symptoms and select the most appropriate treatment (source). These markers can be assessed through blood draws, mucus samples, or simple breathing tests.
As of early 2026, the FDA has approved seven biologic therapies for asthma, covering a range of disease subtypes. These include treatments for allergic asthma, eosinophilic asthma, and type 2 asthma, as well as one biologic — TEZSPIRE — approved for patients who do not fit the traditional type 2 asthma profile (source). Among the newest additions is EXDENSUR (depemokimab-ulaa), which stands out as the first ultra-long-acting biologic in this category, requiring administration only twice yearly rather than every few weeks (source).
Biologics are prescribed as add-on therapies — meaning they supplement, rather than replace, existing treatments. Patients who qualify may experience fewer asthma episodes, reduced emergency visits, diminished reliance on oral corticosteroids, and measurable improvements in lung function (source). However, eligibility depends on a patient’s specific biological profile, making biomarker testing an essential first step in the process.
Clinical Trials: Opening Doors to Tomorrow’s Treatments
Clinical trials serve as the engine behind every new asthma therapy that reaches patients. These structured research studies test new drugs, treatment combinations, surgical tools, and approaches to using existing medications in fresh ways (source). The data gathered through trials forms the scientific foundation that allows new treatments to be approved and made widely available.
Participation in a clinical trial can carry real benefits. Some participants gain early access to treatments not yet available to the general public, and every person who enrolls contributes to a body of medical knowledge that shapes future patient care (source). Ethical safeguards are built into the process: before any trial begins, an Institutional Review Board must review and approve it, confirming that potential risks have been minimized relative to the anticipated benefits (source).
What Researchers Are Working on Right Now
Some of the most exciting work in asthma research is happening through the National Heart, Lung, and Blood Institute (NHLBI). The PrecISE network — short for Precision Interventions for Severe and/or Exacerbation-Prone Asthma — is currently running clinical trials at 30 locations across the country. These trials test five different treatments, each matched to patients based on their individual biology and biomarker profiles, with the goal of making asthma care far more personalized (source).
Beyond personalized medicine, researchers are also pursuing novel drug development strategies. One NHLBI-funded project is engineering the FDA-approved drug niclosamide into an inhaled form, after scientists discovered it can block an ion channel that plays a central role in how asthma develops (source). Separately, an ongoing study is examining whether the antibiotic azithromycin can reduce severe wheezing episodes in young children, exploring whether the drug’s antibacterial properties, its anti-inflammatory effects, or both are responsible for the benefit observed in emergency room settings (source).
Decades of NHLBI-supported research have also helped define who is most at risk for severe asthma. Scientists have identified gender, race, secondhand smoke exposure, obesity, and prior pneumonia as significant risk factors, and have uncovered genetic variations and biomarkers tied to disease severity (source). This growing understanding of asthma’s biological complexity is what makes precision medicine approaches increasingly viable.
Why You Should Learn More About Asthma Treatments
The range of asthma treatments available in the United States has expanded considerably — from time-tested inhalers to biologic therapies tailored to a patient’s specific immune profile, and now to clinical trials testing the next generation of interventions. Each layer of this treatment landscape builds on the last, offering patients and their healthcare providers more precise, effective tools for managing a condition that affects millions of Americans.
Staying informed about developments in biologics, understanding how biomarkers shape treatment decisions, and knowing that clinical trial participation is a real and protected option can meaningfully influence the quality of care a person receives. Asthma management is no longer a one-size-fits-all approach, and the science continues to advance in ways that promise better outcomes for even the most difficult-to-treat cases.